Fidelity Blue Chip Growth: Uninspiring
Editor's note: This is part of a continuing series of articles looking at the 20 biggest no-load stock funds.
The prospects for blue chip stocks are bright, but the outlook for Fidelity Blue Chip Growth is hazy. The fund, which invests in large, fast-growing companies, has ranked in the bottom 30% of its peer group in each of the past four calendar years. Over the past decade, it gained 6% annualized, matching the average large-company growth fund, but lagging the S&P 500-stock index by an average of nearly three percentage points a year.
And now the fund has a new manager. After more than a decade at the helm, manager John McDowell retired in November. His co-manager, Brian Hanson, also left, to concentrate on other funds. Enter Jennifer Uhrig, who previously skippered Fidelity Advisor Equity Growth, a load fund with a mission similar to that of Blue Chip Growth. During her nine-year tenure, Equity Growth performed roughly in line with its peers. But while Blue Chip Growth has been stuck in a rut because McDowell and Hanson clung tightly to an out-of-favor style, Uhrig was able to invest in some medium-sized companies at Equity Growth.
Advertisement
In her nearly three months on the job, Uhrig has guided Blue Chip Growth to a 3% gain. That's still a percentage point behind the S&P 500. The fund's top holdings represent a who's who of, well, blue-chip names. They include Johnson & Johnson, Microsoft, Apple and Wal-Mart. Nearly 10% of the fund's assets were recently in pharmaceuticals, including Merck, Wyeth and Schering-Plough. Altogether, health and technology stocks account for half of assets.
Given Uhrig's uninspiring track record, we see no compelling reasons to stick with Blue Chip. Current shareholders should SELL this fund.
  |
|
Fidelity Blue Chip Growth (FBGRX) |
View updated data for this fund and compare the performance of the 20 biggest no-load stock funds.
Go to A Close Look at the 20 Biggest No-Load Stock Funds.
